Secil TASHAN, Alperen AKSAN, Ayse GULEN ERTURUN, Nurettin BORAN, Ayse Sinem DURU COTELI, Yaprak USTUN
Gynecology Obstetrics & Reproductive Medicine - 2026;32(1):40-45
OBJECTIVE: Our aim was to clearly evaluate the Prognostic Nutritional Index's ability to predict chemotherapy-induced toxicity in ovarian cancer patients undergoing platinum-based chemotherapy. STUDY DESIGN: This retrospective cohort study of 158 patients with epithelial ovarian cancer treated with carboplatin-paclitaxel after surgery at a university hospital from 2010 to 2020 decisively investigates the Prognostic Nutritional Index (PNI) as a predictor of chemotherapy-related toxicities. PNI was calculated using pre-treatment serum albumin levels and lymphocyte counts. RESULTS: The findings clearly demonstrate that patients with a PNI <=34.10 experienced higher overall and severe hematologic toxicities compared to those with a higher PNI. Dose reductions and treatment delays were markedly more frequent in the low PNI group. CONCLUSION: This study establishes that PNI is a valuable tool for assessing patient risk, though further validation will enhance its clinical utility.
